Keeping Future Manufacturing Options Open During Development

Early-stage pharmaceutical development is often focused on formulation performance, stability, and speed to clinic, but the decisions made during this phase can have lasting implications for commercial manufacturing strategies. Maintaining flexibility throughout development requires a broader view of the product lifecycle, including future technology transfer, manufacturing scale-up, supply chain resilience, and intellectual property considerations.

A key challenge is balancing immediate technical requirements with long-term manufacturing goals. Proprietary technologies and manufacturing processes can offer significant advantages during development, yet they may also influence how easily production can be transferred to another facility or contract development and manufacturing organization (CDMO) in the future.

Using softgel development as an example, the discussion highlights how ownership of formulation elements, manufacturing know-how, and associated intellectual property can affect future production options.

Organizations that proactively address these considerations are better positioned to manage growth, establish secondary manufacturing sites, and reduce transfer-related risks. Exploring key questions around technology ownership, transferability, and long-term manufacturing strategy early in development can help preserve valuable options as products progress toward commercialization.